A Review of Methods for Detect Human Papillomavirus Infection

Overview

Journal Virol J

Publisher Biomed Central

Specialty Microbiology

Date 2012 Nov 8

PMID 23131123

Citations 96

Authors

Andre L P Abreu

Raquel P Souza

Fabricia Gimenes

Marcia E L Consolaro

Affiliations

Soon will be listed here.

Abstract

Human Papillomavirus (HPV) is the most common sexually transmitted virus. Worldwide, the most common high-risk (HR)-HPV are -16/18, and approximately 70% of cervical cancers (CC) are due to infection by these genotypes. Persistent infection by HR-HPV is a necessary but not sufficient cause of this cancer, which develops over a long period through precursor lesions, which can be detected by cytological screening. Although this screening has decreased the incidence of CC, HPV-related cervical disease, including premalignant and malignant lesions, continues to be a major burden on health-care systems. Although not completely elucidated, the HPV-driven molecular mechanisms underlying the development of cervical lesions have provided a number of potential biomarkers for both diagnostic and prognostic use in the clinical management of women with HPV-related cervical disease, and these biomarkers can also be used to increase the positive predictive value of current screening methods. In addition, they can provide insights into the biology of HPV-induced cancer and thus lead to the development of nonsurgical therapies. Considering the importance of detecting HPV and related biomarkers, a variety of methods are being developed for these purposes. This review summarizes current knowledge of detection methods for HPV, and related biomarkers that can be used to discriminate lesions with a high risk of progression to CC.

Citing Articles

Development and validation of a multiplex qPCR method for identification of high-risk genotypes of human papillomavirus.

Mohammadi A, Lotfi E, Karamali F, Golab F, Barati M Infect Agent Cancer. 2025; 20(1):15.

PMID: 40055796 PMC: 11889745. DOI: 10.1186/s13027-024-00633-z.

A review of urinary HPV testing for cervical cancer management and HPV vaccine surveillance: rationale, strategies, and limitations.

Cheng L, Wang R, Yan J Eur J Clin Microbiol Infect Dis. 2024; 43(12):2247-2258.

PMID: 39400675 DOI: 10.1007/s10096-024-04963-z.

Empowering the on-site detection of nucleic acids by integrating CRISPR and digital signal processing.

Lee C, Kim H, Degani I, Lee H, Sandoval A, Nam Y Nat Commun. 2024; 15(1):6271.

PMID: 39054353 PMC: 11272939. DOI: 10.1038/s41467-024-50588-3.

Human Papillomavirus and Associated Cancers: A Review.

Jensen J, Becker G, Jackson J, Rysavy M Viruses. 2024; 16(5).

PMID: 38793561 PMC: 11125882. DOI: 10.3390/v16050680.

Cervical cytology and HPV distribution in Cape Verde: A snapshot of a country taken during its first HPV nation-wide vaccination campaign.

Vieira R, Montezuma D, Barbosa C, Macedo Pinto I Tumour Virus Res. 2024; 17:200280.

PMID: 38621479 PMC: 11240291. DOI: 10.1016/j.tvr.2024.200280.

References

Gallo G, Bibbo M, Bagella L, Zamparelli A, Sanseverino F, Giovagnoli M . Study of viral integration of HPV-16 in young patients with LSIL. J Clin Pathol. 2003; 56(7):532-6. PMC: 1770000. DOI: 10.1136/jcp.56.7.532. View

Lenselink C, de Bie R, Hamont D, Bakkers J, Quint W, Massuger L . Detection and genotyping of human papillomavirus in self-obtained cervicovaginal samples by using the FTA cartridge: new possibilities for cervical cancer screening. J Clin Microbiol. 2009; 47(8):2564-70. PMC: 2725671. DOI: 10.1128/JCM.00285-09. View

Xi L, Koutsky L, Castle P, Wheeler C, Galloway D, Mao C . Human papillomavirus type 18 DNA load and 2-year cumulative diagnoses of cervical intraepithelial neoplasia grades 2-3. J Natl Cancer Inst. 2009; 101(3):153-61. PMC: 2724855. DOI: 10.1093/jnci/djn461. View

Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand M . Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008; 26 Suppl 10:K29-41. DOI: 10.1016/j.vaccine.2008.06.019. View

Didelot M, Boulle N, Damay A, Costes V, Segondy M . Comparison of the PapilloCheck® assay with the digene HC2 HPV DNA assay for the detection of 13 high-risk human papillomaviruses in cervical and anal scrapes. J Med Virol. 2011; 83(8):1377-82. DOI: 10.1002/jmv.22148. View

Hesselink A, van Ham M, Heideman D, Groothuismink Z, Rozendaal L, Berkhof J . Comparison of GP5+/6+-PCR and SPF10-line blot assays for detection of high-risk human papillomavirus in samples from women with normal cytology results who develop grade 3 cervical intraepithelial neoplasia. J Clin Microbiol. 2008; 46(10):3215-21. PMC: 2566115. DOI: 10.1128/JCM.00476-08. View

Cricca M, Venturoli S, Leo E, Costa S, Musiani M, Zerbini M . Disruption of HPV 16 E1 and E2 genes in precancerous cervical lesions. J Virol Methods. 2009; 158(1-2):180-3. DOI: 10.1016/j.jviromet.2009.01.005. View

Monnier-Benoit S, Dalstein V, Riethmuller D, Lalaoui N, Mougin C, Pretet J . Dynamics of HPV16 DNA load reflect the natural history of cervical HPV-associated lesions. J Clin Virol. 2005; 35(3):270-7. DOI: 10.1016/j.jcv.2005.09.001. View

Rahman M, Sasagawa T, Yamada R, Kingoro A, Ichimura H, Makinoda S . High prevalence of intermediate-risk human papillomavirus infection in uterine cervices of Kenyan women infected with human immunodeficiency virus. J Med Virol. 2011; 83(11):1988-96. DOI: 10.1002/jmv.22203. View

10.

Schopp B, Holz B, Zago M, Stubenrauch F, Petry K, Kjaer S . Evaluation of the performance of the novel PapilloCheck HPV genotyping test by comparison with two other genotyping systems and the HC2 test. J Med Virol. 2010; 82(4):605-15. DOI: 10.1002/jmv.21719. View

11.

Kocjan B, Seme K, Poljak M . Comparison of the Abbott RealTime High Risk HPV test and INNO-LiPA HPV Genotyping Extra test for the detection of human papillomaviruses in formalin-fixed, paraffin-embedded cervical cancer specimens. J Virol Methods. 2011; 175(1):117-9. DOI: 10.1016/j.jviromet.2011.04.006. View

12.

. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum. 2008; 90:1-636. PMC: 4781057. View

13.

Ho C, Lee B, Chang S, Chien T, Huang S, Yan C . Integration of human papillomavirus correlates with high levels of viral oncogene transcripts in cervical carcinogenesis. Virus Res. 2011; 161(2):124-30. DOI: 10.1016/j.virusres.2011.06.012. View

14.

SANGER F, Nicklen S, Coulson A . DNA sequencing with chain-terminating inhibitors. 1977. Biotechnology. 1992; 24:104-8. View

15.

Camargo M, Soto-De Leon S, Sanchez R, Munoz M, Vega E, Beltran M . Detection by PCR of human papillomavirus in Colombia: Comparison of GP5+/6+ and MY09/11 primer sets. J Virol Methods. 2011; 178(1-2):68-74. DOI: 10.1016/j.jviromet.2011.08.014. View

16.

Johnson L, Starkey C, Palmer J, Taylor J, Stout S, Holt S . A comparison of two methods to determine the presence of high-risk HPV cervical infections. Am J Clin Pathol. 2008; 130(3):401-8. DOI: 10.1309/4DXEAFG2JXYF34N3. View

17.

Lee L, Connell C, Woo S, Cheng R, McArdle B, Fuller C . DNA sequencing with dye-labeled terminators and T7 DNA polymerase: effect of dyes and dNTPs on incorporation of dye-terminators and probability analysis of termination fragments. Nucleic Acids Res. 1992; 20(10):2471-83. PMC: 312381. DOI: 10.1093/nar/20.10.2471. View

18.

Mateos M, de Antonio J, Rodriguez-Dominguez M, Sanz I, Rubio M . [Evaluation of a prototype real-time PCR assay for the separate detection of human papilloma virus genotypes 16 and 18 and other high risk human papillomavirus in cervical cancer screening]. Enferm Infecc Microbiol Clin. 2011; 29(6):411-4. DOI: 10.1016/j.eimc.2011.01.007. View

19.

Forinash A, Yancey A, Pitlick J, Myles T . Safety of the HPV Bivalent and Quadrivalent Vaccines During Pregnancy. Ann Pharmacother. 2011; 45(2):258-62. DOI: 10.1345/aph.1P396. View

20.

Santiago E, Camacho L, Junquera M, Vazquez F . Full HPV typing by a single restriction enzyme. J Clin Virol. 2006; 37(1):38-46. DOI: 10.1016/j.jcv.2006.06.001. View